Several new Alzheimers drugs have been shown to clearly slow the disease by removing a toxic protein called amyloid from the brains of early Alzheimer’s patients. The drugs are getting approved by the FDA and most likely, will be accepted by Medicare as a treatment. It sets the stage for a potential head-to-head competition between Lilly and Eisai, as more patients with early Alzheimer’s gravitate to the idea of preventing the loss of memories and brain function. The facts in the Market Intel Segment, then we'll dive into the proven methods of selecting high value stocks.  MASTERING MONEY is on the air.